TABLE 2

The Impact of the Vancomycin Guidelines on Clinically Relevant Variables Using Standard Statistics

Preguideline Population (N = 49)Postguideline, Compliant Population (N = 67)Relative Risk (Effect Size)P
PITT, %6.1 (N = 3)20.9 (N = 14)2.63.03a,*
Patients with first trough 10–20 µg/mL, %8.2 (N = 4)40.3 (N = 27)4.10<.001a,*
TTT mean d (95% CI)2.78b (1.99–3.56)1.56c (1.22–1.89)N/A.001d,*
Patients with vancomycin-related toxicitye, %6.1 (N = 3)4.5 (N = 3)0.84.70d
  • PITT: 10–15 µg/mL for patients with mild/moderate infections and 15–20 µg/mL for patients with MRSA/severe infections. N/A, not applicable.

  • a Fisher’s exact test.

  • b In 18 patients who achieved a therapeutic tough during hospitalization.

  • c In 31 patients who achieved a therapeutic tough during hospitalization.

  • d Unpaired t test.

  • e Excluding red man syndrome. All toxicities documented were vancomycin-related acute kidney injury.

  • * P < .05.